MedTrace Logo

Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.

NCT06294483 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-03-05

No results posted yet for this study

Summary

The present study aims to:

Compare clinical features, hematological indices and disease activity between the early-onset and late-onset patients with systemic lupus erythematosus.

Evaluate the relationship between hematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and Systemic lupus erythematosus (SLE) disease manifestations and activity.

Conditions

Interventions

DIAGNOSTIC_TEST

CBC

Is used to detect haematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and its relation to disease activity

DIAGNOSTIC_TEST

Antinuclear Antibody tests (ANA)

To be tool in diagnosis of SLE

DIAGNOSTIC_TEST

Rest of ANA profile

As tool of diagnosis of SLE

DIAGNOSTIC_TEST

C3 and C4 complement level.

As method of detection of acute acivity of SLE

DIAGNOSTIC_TEST

Anti phospholipid marker

To detect antiphospholipid syndrome if there is sign of thrombosis

DIAGNOSTIC_TEST

Serum creatinine and Alb/create ratio

To detct complication of disease on kidney

OTHER

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Is criteria of diagnosis of SLE

OTHER

SLEDAI scores

Is score to detect the activity of disease

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-10
Primary Completion
2024-07-30
Completion
2024-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06294483 on ClinicalTrials.gov